top of page
WHERE DOES THE MONEY GO?
USING POLYGENIC RISK MODIFICATION TO IMPROVE BREAST CANCER PREVENTION: THE PRIMO TRIAL.
2020 - 2023
Peter MacCallum Cancer Centre
A/Prof. Paul James
Genomic testing will be used to identify women who can benefit the most from preventative strategies. Outcomes from this study will lead to the implementation of personalised risk management.
The trial will compare the current standard of care with a personalised assessment of the risk of breast and ovarian cancer that includes 'single gene' testing, family history, personal risk factors and research genomic testing (PRS).
bottom of page